Statistical analysis
EVENT
Participants who received at least one dose of randomised treatment (FCZ or AMB) were included in the safety analysis. Participants whose baseline CSF culture did not grow Comparisons for continuous data across the four cohorts used a Kruskal-Wallis test and a Wilcoxon rank sum test for pairwise comparisons. Categorical variables were tested with a Chi-square test. Within arm changes from baseline were tested with a Wilcoxon signed rank test. Time to event data were summarized using the methods of Kaplan-Meier with Greenwood’s confidence intervals and log rank tests. Safety results are presented with 95% confidence intervals (CIs). In this phase I/II study, efficacy results are presented with 90% CIs to allow for non-definitive signals of efficacy between FCZ and AMB. No adjustments were made for multiple comparisons.